Gyre COO sells shares after option exercise

GYRE THERAPEUTICS, INC.

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported an exercise-and-sell sequence in company stock. On June 9 and 10, 2026, he sold a total of 20,918 shares of common stock in open-market transactions at reported prices of $6.14 and $6.21 per share, with actual sales executed across price ranges detailed in the footnotes.

On the same dates, he exercised stock options to acquire the same total of 20,918 shares of common stock at an exercise price of $0.75 per share. Following these transactions, he directly held 700,000 shares of common stock. The options exercised were reported as vested in full, and no remaining derivative positions are listed in this filing.

Insider Trade Summary

Exercise and Sale: 20,918 shares ($113K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Ye Weiguo

Role Chief Operating Officer

Sold 20,918 shs ($129K)

Approx. gross sale proceeds $129K

Approx. exercise cost $16K

Approx. pre-tax spread $113K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	6,418	$0.00	$0.00
Exercise	Common Stock	6,418	$0.75	$5K
Sale	Common Stock	6,418	$6.21	$40K
Exercise	Stock Option (Right to Buy)	14,500	$0.00	$0.00
Exercise	Common Stock	14,500	$0.75	$11K
Sale	Common Stock	14,500	$6.14	$89K

Holdings After Transaction: Stock Option (Right to Buy) — 841,501 contracts (Direct); Common Stock — 700,000 shares (Direct)

Footnotes (3)

1. F1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0597 to $6.19. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.11 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. These options are vested in full.

Key Figures

Shares sold: 20,918 shares Sale price June 9: $6.14 per share Sale price June 10: $6.21 per share +5 more

8 metrics

Shares sold 20,918 shares Total common stock sold June 9–10, 2026

Sale price June 9 $6.14 per share Reported weighted average sale price on June 9, 2026

Sale price June 10 $6.21 per share Reported weighted average sale price on June 10, 2026

Options exercised 20,918 shares Total shares acquired via option exercises

Option exercise price $0.75 per share Exercise price for stock options converted to common

Shares held after 700,000 shares Direct common stock ownership after transactions

Net share change -20,918 shares Net buy/sell shares from transaction summary

Option expiration October 31, 2030 Expiration date of options that were exercised

Key Terms

weighted average sale price, Stock Option (Right to Buy), derivative security, open-market sale, +1 more

5 terms

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for derivative entries"

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"transaction_action: "open-market sale" for common stock transactions"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

vested in full financial

"Footnote F3 states: "These options are vested in full.""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GYRE COO Weiguo Ye report in this Form 4?

COO Weiguo Ye reported selling 20,918 shares of Gyre Therapeutics common stock while exercising stock options for the same number of shares. The activity occurred over June 9–10, 2026, in open-market transactions and option exercises disclosed in the filing.

How many GYRE shares did the COO sell and at what reported prices?

Weiguo Ye sold 20,918 shares of Gyre Therapeutics common stock. Reported weighted average sale prices were $6.14 per share on June 9, 2026, and $6.21 per share on June 10, 2026, with actual trades within stated price ranges.

What stock options did the GYRE COO exercise in this filing?

He exercised options covering 20,918 shares of Gyre Therapeutics common stock at an exercise price of $0.75 per share. The options were described as vested in full, and the transactions were reported as derivative exercises or conversions.

How many GYRE shares does COO Weiguo Ye hold after these transactions?

After the reported sales and option exercises, COO Weiguo Ye directly holds 700,000 shares of Gyre Therapeutics common stock. This figure reflects his direct ownership position immediately following the June 9–10, 2026 transactions disclosed in the Form 4.

Were the GYRE share sales by the COO made in the open market?

Yes. The Form 4 classifies the 20,918 shares sold by COO Weiguo Ye as open-market sales or private transactions. Footnotes note weighted average prices and specify that individual trades occurred within defined price ranges on each transaction date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ye Weiguo

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		M		14,500	A	$0.75	714,500	D
Common Stock	06/09/2026		S		14,500	D	$6.14(1)	700,000	D
Common Stock	06/10/2026		M		6,418	A	$0.75	706,418	D
Common Stock	06/10/2026		S		6,418	D	$6.21(2)	700,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.75	06/09/2026		M			14,500	(3)	10/31/2030	Common Stock	14,500	$0	847,919	D
Stock Option (Right to Buy)	$0.75	06/10/2026		M			6,418	(3)	10/31/2030	Common Stock	6,418	$0	841,501	D

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0597 to $6.19. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.11 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. These options are vested in full.

	/s/ Weiguo Ye	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)